Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

rintodestrant

An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, rintodestrant specifically targets and binds to the estrogen receptor alpha (ERalpha; ERa; ESR1) and induces a conformational change that promotes ERalpha degradation and downregulation. This prevents ERalpha-mediated signaling and inhibits both the growth and survival of ERalpha-expressing cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:selective estrogen receptor degrader G1T48
selective estrogen receptor downregulator G1T48
Code name:G1T48
SERD G1T48
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search